The action of beta-adrenergic agonists on pulmonary surfactant secretion requires lung cell membrane beta-adrenergic receptors. In the fetus, the density of beta-adrenergic receptors in lung increases in the latter stages of gestation. The increase in density can also be induced by maternal glucocorticoid treatment. In this study, we measured beta-adrenergic receptors in developing rat lung by (-) [3H1-dehydroalprenalol (DHA) biding and confirmed the increase in beta-adrenergic receptors late in gestation. To determine if glucocorticoids have a direct effect on fetal lung to regulate beta-adrenergic receptors, we cultured fetal lung explants with dexamethasone. Treated explants had increased DHA b i ding compared with controls (138.0 f 8.8 versus 63.2 f 5.0 fmole/ mg membrane protein). Scatchard analysis revealed that the increased DHA biding was due to an increase in maximum receptor number. There was dso a significant difference in the dissociation constant of the treated and control explants (0.85 f 0.07 nM versus 0.43 f 0.08 nM, respectively; P < 0.05), suggesting that the receptors induced by dexamethasone were of lower binding affmity. Cyclohexamide, an inhibitor of protein synthesis, completely eliminated the dexamethasone induced increase in DHA binding. These data indicate that glucocorticoids have a direct effect on fetal lung to increase beta-adrenergic receptor density and that new protein synthesis is required for this effect. Abbreviation DHA, dehydroalprenalol Secretion of pulmonary surfactant by type I1 pneumocytes is essential for maintenance of alveolar stability after birth. Recent studies of adult type I1 pneumocytes indLate that surfactant phospholipid secretion is responsive to beta-adrenergic agonists (3, 6). With respect to developing lung, acute fetal injection or maternal pretreatment with several beta-adrenergic agonists produces an increased lecithin/sphingomyelin ratio in fetal lung lavage and pressure-volume relationships indicative of increased alveolar surfactant (1, 2, 7, 12). These effects may be dependent on gestational age: beta-adrenergic stimulation of surfactant efflux is most marked in the most mature fetuses (13).
SUMMARY
The action of beta-adrenergic agonists on pulmonary surfactant secretion requires lung cell membrane beta-adrenergic receptors. In the fetus, the density of beta-adrenergic receptors in lung increases in the latter stages of gestation. The increase in density can also be induced by maternal glucocorticoid treatment. In this study, we measured beta-adrenergic receptors in developing rat lung by (-) [3H1-dehydroalprenalol (DHA) biding and confirmed the increase in beta-adrenergic receptors late in gestation. To determine if glucocorticoids have a direct effect on fetal lung to regulate beta-adrenergic receptors, we cultured fetal lung explants with dexamethasone. Treated explants had increased DHA b i ding compared with controls (138.0 f 8.8 versus 63.2 f 5.0 fmole/ mg membrane protein). Scatchard analysis revealed that the increased DHA biding was due to an increase in maximum receptor number. There was dso a significant difference in the dissociation constant of the treated and control explants (0.85 f 0.07 nM versus 0.43 f 0.08 nM, respectively; P < 0.05), suggesting that the receptors induced by dexamethasone were of lower binding affmity. Cyclohexamide, an inhibitor of protein synthesis, completely eliminated the dexamethasone induced increase in DHA binding. These data indicate that glucocorticoids have a direct effect on fetal lung to increase beta-adrenergic receptor density and that new protein synthesis is required for this effect.
Abbreviation

DHA, dehydroalprenalol
Secretion of pulmonary surfactant by type I1 pneumocytes is essential for maintenance of alveolar stability after birth. Recent studies of adult type I1 pneumocytes indLate that surfactant phospholipid secretion is responsive to beta-adrenergic agonists (3, 6) . With respect to developing lung, acute fetal injection or maternal pretreatment with several beta-adrenergic agonists produces an increased lecithin/sphingomyelin ratio in fetal lung lavage and pressure-volume relationships indicative of increased alveolar surfactant (1, 2, 7, 12). These effects may be dependent on gestational age: beta-adrenergic stimulation of surfactant efflux is most marked in the most mature fetuses (13) .
The cellular effects of beta-adrenergic agonists are mediated through specific cell membrane receptors. Both beta-1 and beta-2 type receptors have been identified in membrane preparations from adult and developing lung (9, 18,2 1,24). In developing lung, receptor concentration increases in the latter part of gestation, a time of rapid cellular differentiation. Several recent studies have suggested hormonal control of pulmonary beta-adrenergic receptor density in both adult and fetal lung. Cortisol treatment enhanced isoproterenol-induced surfactant secretion in the A549 pulmonary adenocarcinoma cell line (20) . In a cultured human lung cell line, hydrocortisone augmented beta-adrenergic receptor synthesis (8) . Adrenalectomy of adult rats produced a decrease in pulmonary receptor concentration that was restored with hydrocortisone treatment (17) . In the rabbit fetus, Cheng et. al. (5) found an increase in beta-adrenergic receptors in fetal lung membranes after maternal treatment with betamethasone. Thyroid hormone may regulate postnatal pulmonary beta-adrenergic receptors (23) .
We studied the development of pulmonary beta-adrenergic receptors in fetal rat lung. To examine the direct effect of glucocorticoids on lung beta-adrenergic receptors, fetal lung explants were cultured with dexamethasone. These experiments demonstrated: (1) a marked increase in lung beta-adrenergic receptor concentration during development; (2) a direct influence of glucocorticoids on fetal lung beta-adrenergic receptor concentration; and (3) a requirement for protein synthesis in the production of new beta-adrenergic receptors.
MATERIALS AND METHODS
Animals.
Timed gestation pregnant Sprague-Dawley rats were obtained from Charles River Laboratories (Wilmington, MA). Animals were killed by decapitation and tissues removed in the cold.
Beta-adrenergic receptor analysis. Fetal lung, brain, and heart were dissected free from extraneous material, weighed, and minced with fine surgical scissors for 1 min. They were homogenized in a 10-fold volume of 50 mM Tris-HC1, pH 7.7, at 22°C in a glass vessel with a teflon pestle for 1 min at a setting of 10 with a Caframo stirrer-homogenizer (CSA, Wiarton, Ontario, Canada). The homogenate was transferred to centrifuge tubes and combined with washings of the vessel and pestle. The homogenate was centrifuged for 20 rnin at 50,000 x g at 4"C, and the pellet was resuspended in a small volume of buffer and rehomogenized as above. It was transferred to a Dounce homogenizer (Wheaton Scientific, Millville, NJ) and further homogenized for 1 min. Receptor assays were performed immediately after the final homogenization. The final tissue dilution was 1:20.
The beta-adrenergic receptor assay was a modification of the technique described by Cabelli et al. (4) using DHA binding to the membrane preparation. Binding assays were performed in a reaction mixture consisting of Krebs-Ringer phosphate, pH 7.4, containing 0.2% albumin, 200 pM sodium metabisulfite, 100 pM phentolamine, and 24 nM DHA in a final volume of 0.5 ml. The assay was initiated by the addition of 300 p1 of tissue homogenate (6-15 mg tissue) suspended in Krebs-Ringer phosphate, pH 7.4, containing 0.2% albumin and 200 pM sodium metabisulfite to the prewarmed reaction mixture in 12 x 75 test tubes. After incubation at 37°C with constant low speed shaking for 20 min, the reaction was terminated by adding 2.5 ml of ice cold wash buffer (50 mM Tris-HC1, pH 7.4, 10 mM MgC12) to each tube. The contents of the tube were rapidly filtered under constant vacuum through a single Whatman GF/C filter (24-mm diameter) that had been prewashed with 24 pM alprenolol. The incubation tubes were rinsed twice and the filters washed six times with 2.5 ml aliquots of ice cold wash buffer. The filters were placed directly into glass scintillation vials, scintillation fluid was added to each vial and radioactivity determined. Control tubes containing no tissue were included in all experiments. Specific binding was defmed as the total amount of DHA bound less the nonspeciiic radioligand binding. Nonspecific binding was determined by assaying the bound radioligand in the presence of 6 pM (+) propranolol. Under the conditions employed, specific binding was approximately 40% of the total DHA bound to the membrane preparation.
Fetal lung explants. Lung organ explants were prepared from 19 day gestation fetal rats as described previously with slight modifications (10, 16) . Culture medium was Waymouth's MB 752/1 supplemented with 100 p/ml penicillin and 100 pg/ml streptomycin, but not containing serum. The explants were placed on lines scratched into 60 mm2 culture dishes and the culture dishes were placed in a sealed chamber, flushed with 95% 025% CO2, and rocked from side to side (3 cycles/min). The medium of both control and treated explants was changed daily. At the end of culture (48 h), the explants were analyzed fresh for protein and receptor concentration. The concentrations of dexamethasone and cyclohexamide used in these experiments gave the maximal response in preliminary studies (data not shown) and were similar to those used in previous studies of lung explants (1 1).
Protein was determined by the method of Lowry et al. (14) with bovine serum albumin as the standard.
Chemicals. Culture medium was obtained from Grand Island Biologicals (Grand Island, NY). Biochemicals were obtained from Sigma Co., St. Louis, MO. Radiolabeled chemicals were purchased from New England Nuclear (Boston, MA).
RESULTS
Beta-adrenergic receptor concentration during development.
The developmental pattern of beta-adrenergic receptor concentration in lung is shown in Figure 1 . For comparison, data were also obtained for brain and heart tissue. In fetal lung, beta-adrenergic receptor concentration increased 2-3-fold between 19 and 21 days gestation. This was followed by a further increase on the day after birth. By contrast, beta-adrenergic receptor concentration of brain did not change during this period of development, whereas heart tissue showed some increase in receptor content. This increased pulmonary beta-adrenergic receptor concentration during the late stages of gestation is in agreement with data from others (9, 24). There are no comparison data for heart and brain receptors during this developmental period. Beta-adrenergic receptors in fetal lung explants. Specific DHA binding to a membrane preparation of the fetal lung explants was saturable. Scatchard analysis (Fig. 2) was linear, indicating uniform DHA binding to receptor sites. During the 48-h culture period, specific DHA binding did not increase appreciably compared to the increase seen in vivo at the corresponding gestational ages (Fig. 3) . Addition of lpM dexamethasone to the cultures for 48 h resulted in an increase in specific DHA binding compared to (Fig. 3) , suggesting that the time required for the glucocorticoid effect was less than 24 h. Scatchard analysis of DHA binding in control and treated explants (Fig. 2) revealed that the treated explants had an increased content of receptors, as reflected by the 3-fold increase in extrapolated maximum binding. The dissociation constant (Kd) of the treated explants was significantly greater than controls (0.85 k 0.07 nM versus 0.43 rt: 0.08 nM; P < 0.05), indicating that the receptors in the treated explants were of lower binding affinity compared to controls. Because DHA binds with equal affinity to beta-1 and beta-2 adrenergic receptors, it is not possible to determine from these experiments if the relative concentrations of these subclasses was affected by dexamethasone; thus, the effect of dexamethasone was to induce an increased number of receptors with an average lower binding affinity. Increases in receptor number can indicate either "up regulation," the exposure of previously unexposed receptors, or synethsis of new receptors. Inasmuch as glucocorticoid effects are frequently mediated by new protein synthesis, we examined the effects of cyclohexamide, an inhibitor of protein synthesis, on DHA binding in the control and dexamethasone treated lung explants. In these experiments all additions to the media were made only for the final 24 h of culture. Explants cultured in 50 pM cyclohexamide only (Fig. 4) had DHA binding at 48 h that was similar to controls cultured with no additions. This suggests that cyclohexamide was not generally toxic to the tissues. In explants cultured with 1 pM dexamethasone plus 50 pM cyclohexamide for the final 24 h, there was a blunting of the dexamethasone-induced increase in receptor density. These data indicate that new protein synthesis is required for the dexamethasone effect on beta-adrenergic receptors.
DISCUSSION
The increased beta-adrenergic receptor concentration of fetal lung, demonstrated in this and other studies (9, 24) , occurs at a time of rapid cellular differentiation of the fetal lung and development of the surfactant system (15, 22, 25) . Several lines of evidence suggest that beta-adrenergic agonists augment surfactant secretion or synthesis in fetal lung (1-3, 6, 7, 12) . Gestational agedependent increases in beta-adrenergic receptor concentration may account for the relative lack of response to these agonists in the~immature fetus (13) . The increase inbeta-adrenergic;eceptors during gestation is thought to be due to increased receptor number rather than increased binding affinity (9); both beta-1 and beta-2 subclasses increase with advancing gestation (24) .
The cellular distribution of beta-adrenergic receptors in fetal lung is not known. In adult lung, isolated type I1 pneumocytes respond to beta-adrenergic agonists with increased surfactant secretion, implying that these cells possess beta-adrenergic receptors. Evidence documenting these receptors on membranes from isolated adult type I1 pneu&ocytes hasbeen reported (19) .
The factors that regulate lung beta-adrenergic receptor density during development are not precisely known, although glucocorticoids and thyroid hormone have been implicated (5, 23) . Using an explant model of fetal lung, we have documented a direct effect of dexamethasone on beta-adrenergic receptor number. Previous studies, in which pregnant rabbits were injected with glucocorticoids, could not specify a direct effect on fetal lung, because countemalent hormonal and metabolic responses to treatment were not known. Our finding that control explants had no increase in beta-adrenergic receptors whereas explants treated with dexamethasone had increased receptor concentration similar to that of fresh tissue suggests that glucocorticoids may also induce receptors in vivo. Further evidence that glucorcorticoids participate in regulating pulmonary beta-adrenergic receptors in vivo is suggested by finding a decrease in receptor concentration in adrenalectomized animals that was reversed by exogenous hydrocortisone treatment (17) .
In the present study, the predominant effect of glucocorticoid treatment was an increase in beta-adrenergic receptor number. This concurs with results of other studies in fetal (5) and adult lung (17) . In agreement with studies of Mano et al. (17) in adult lung, we found a decrease in receptor binding affinity for DHA after glucocorticoid treatment. Other studies in fetal lung showed no change in binding affinity after glucocorticoid treatment (5) . The decrease in receptor affinity of the explants cultured in glucocorticoid suggests induction of a different class of receptors from those which predominate in untreated explants.
The molecular basis for increased beta-adrenergic receptor concentration in glucocorticoid-treated lung is suggested by this and other studies. In a cultured human cell line, glucocorticoids produced an increased rate of receptqr synthesis that resulted in a higher steady state of membrane receptor concentration within 24 h (8). In the present study the glucocorticoid effect was largely eliminated in explants also cultured in cyclohexamide, an inhibitor of protein synthesis. This suggests that the increase in receptor number induced by dexamethasone required new protein synthesis.
The distribution among the various fetal lung cells of betaadrenergic receptors is entirely speculative. The fetal lung is composed of a heterogeneous population of cells, and the specific cellular site of the beta-adrenergic receptors induced by glucocorticoids cannot be defined from this or the previous studies. Because mature type I1 pneumocytes possess beta-adrenergic receptors, and glucocorticoids induce maturation of other aspects of type I1 cell function in fetal lung, a likely site of the glucocorticoid induced receptors is the differentiating type I1 cell.
